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Abstract
Background: West Nile virus (WNV) is a neurotropic flavivirus that has emerged globally as a significant cause of
viral encephalitis in humans. Herein, we investigated the immunological responses induced by two phylogenetically
related WNV strains of lineage 1, WNV NY99, and WNV Eg101.
Methods: Eight-week-old C57BL/6J mice were inoculated with WNV NY99 or WNV Eg101 and mortality, virus
burden in the periphery and brain, type 1 interferon response, WNV-specific antibodies, leukocyte infiltration, and
inflammatory responses were analyzed.
Results: As expected, WNV NY99 infected mice demonstrated high morbidity and mortality, whereas no morbidity
and mortality was observed in WNV Eg101 infected mice. Virus titers were comparable in the serum of both WNV
NY99 and WNV Eg101 infected mice at day 3 after inoculation; however, at day 6, the virus was cleared from WNV
Eg101 infected mice but the virus titer remained high in the WNV NY99 infected mice. Virus was detected in the
brains of both WNV NY99 and Eg101 infected mice, albeit significantly higher in the brains of WNV NY99 infected
mice. Surprisingly, levels of type 1 interferon and WNV-specific antibodies were significantly higher in the serum
and brains of WNV NY99 infected mice. Similarly, protein levels of multiple cytokines and chemokines were significantly
higher in the serum and brains of WNV NY99 infected mice. In contrast, we observed significantly higher numbers of
innate and adaptive immune cells in the spleens and brains of WNV Eg101 infected mice. Moreover, total number and
percentage of IFN-γ and TNF-α producing WNV-specific CD8+ T cells were also significantly high in WNV Eg101 infected
mice.
Conclusions: Our data demonstrate that induction of virus-specific effector immune cell response limits virus
replication and severe WNV disease in Eg101 infected mice. Our data also demonstrate an inverse correlation between
leukocyte accumulation and production of pro-inflammatory mediators in WNV-infected mice. Moreover, increased
production of pro-inflammatory mediators was associated with high-virus titers and increased mortality in WNV NY99
infected mice.
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Background
West Nile virus (WNV), a neurotropic flavivirus, has
emerged as a significant cause of viral encephalitis in the
USA [1]. WNV infection in humans is usually asymptom-
atic or self-limiting, with a mild febrile illness, but may
progress to meningitis, encephalitis, paralysis, and death.
Until 1999, WNV was geographically distributed in Africa,
the Middle East, western and central Asia, India, and
Europe, where it caused sporadic cases of febrile dis-
ease and occasional outbreaks of encephalitis in elderly
people and in equines [2, 3]. The unexpected emer-
gence of WNV in the USA in 1999 was associated with
the introduction of the NY99 strain, which is more viru-
lent, and resulted in higher incidence of meningoenceph-
alitis in humans as compared to the non-virulent strains
such as the WNV Eg101 strain [4, 5]. Recent outbreaks of
highly virulent WNV strains have also been reported in
the Mediterranean basin, southern Europe, and Russia
[6, 7]. Although the worldwide incidence of WNV in-
fection is increasing, there is no specific treatment or
vaccine available for use in humans.
Studies using the well-characterized WNV encephalitis
(WNVE) mouse models show that an intact innate and
adaptive immune response is required to limit WNV in-
fection. Antiviral type I interferon production is essential
in suppressing viral titers in the brain and peripheral
organs [8]. The induction of WNV-specific immuno-
globulins is essential for suppressing viremia and virus
dissemination [9]. In the central nervous system (CNS),
neurons are the primary target of WNV replication,
and virus-associated pathology is characterized by
neuronal death, activation of glial cells, and massive in-
filtration of leukocytes in the perivascular space and
parenchyma. The migration of leukocytes into the brain
is essential for controlling WNV infection in the brain
[10–12]. WNV also induces a dramatic increase in sev-
eral pro-inflammatory cytokines such as tumor necrosis
factor alpha (TNF-α) and interleukin (IL)-1β and che-
mokines such as CCl2 and CXCL10, which regulate
leukocyte trafficking into the brain and neuronal death
after infection [11, 13, 14]. The global increase of WNV
neuroinvasive disease warrants a greater understanding
of the molecular mechanisms associated with virus
clearance and neuroinflammation.
The WNV strain Eg101 was isolated from human
blood in Egypt in 1950 [15]. NY99 and Eg101 strains of
WNV are 95.4 and 99.6 % identical at the nucleotide
and amino acid levels, respectively. Both the WNV
NY99 and WNV Eg101 strains are classified in same
genotypic lineage and belong to same clade 1a of the
lineage 1 [5, 16]. Lineage 1 strains are considered emer-
ging and associated with outbreaks of neuroinvasive dis-
ease [5]. While the WNV NY99 strain is highly
pathogenic and implicated in large-scale mortality, the
WNV Eg101 strain is largely non-pathogenic. We have
previously demonstrated that mice immunized with both
1000 and 100 plaque-forming units (PFU) of WNV
Eg101 demonstrated 100 % protection against both sub-
cutaneous and intracranial challenge with a lethal dose
(1000 PFU) of the WNV NY99 strain [17]. However, the
underlying mechanisms associated with differential patho-
genesis of lethal, WNV NY99, and non-lethal, WNV
Eg101, strains are largely unknown. We hypothesized that
differential host immune response is the critical determin-
ant of distinct disease outcome associated with the WNV
NY99 and WNV Eg101 strains. In the present study, we
examined the immunological changes in the serum and
brain of mice during WNV NY99 strain and WNV Eg101
strain infection to understand the underlying immuno-
pathological mechanisms leading to severe WNV disease.
While both strains were neuroinvasive in adult mice, our
results revealed phenomenal differences in the clinical dis-
ease, induction of type 1 interferon and WNV-specific
antibodies, innate and adaptive immune cell response, and
inflammatory response in the periphery and in the brain.
Methods
Ethics statement
This study was specifically approved by the University of
Hawaii Institutional Animal Care and Use Committee
(IACUC) (protocol number 13–1759), and conducted in
strict accordance with guidelines established by the
National Institutes of Health and the University of
Hawaii IACUC. All animal experiments were con-
ducted in consultation with veterinary and animal
care staff at the University of Hawaii in animal bio-
safety level-3 laboratory, and mice that exhibited se-
vere disease were euthanized to limit suffering. The
animal suite was maintained at 72 °F, 45 % humidity,
and on 12/12-light/dark cycle. Sawdust bedding was
provided along with paper towels.
WNV infection experiments
Eight-week-old C57BL/6J mice were purchased from the
Jackson Laboratory. Mice were inoculated via the foot-
pad route with 100 plaque-forming units (PFU) of Eg101
or NY99 strains of WNV [17, 18]. On specific days after
inoculation, 100 μL of blood was collected from the tail
vein, and serum was separated and frozen at −80 °C for fur-
ther analysis. At days 3, 6, 8, and 10 after inoculation, mice
were anesthetized using isoflurane and perfused with cold
PBS [19, 20]. WNV infection is first detected in the brain
between days 4 and 6 after footpad inoculation, and peak
virus load is observed at days 8 and 10 after inoculation.
Similar to humans, WNV-infected mice demonstrate vari-
ous neurological symptoms such as paresis, hind limb par-
alysis, tremors, and ataxic gait [21]. In our model, these
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symptoms appear at day 8 after inoculation. Mortality is ob-
served between days 8 and 12 after inoculation [19, 20].
Brains were harvested and flash frozen in 2-methylbutane
and stored at −80 °C until further processing. Frozen brain
tissues were weighed and homogenized in a bullet blender
using glass or zirconium oxide beads. WNV titers in the
serum and brain homogenates were measured by plaque
assay using Vero cells [20, 22]. Alternatively, mice were per-
fused with PBS followed by 4 % paraformaldehyde (PFA),
and brains were harvested, cryoprotected in 30 % sucrose,
and embedded in the optimum cutting temperature (OCT)
media [23]. In separate experiments, brains and spleens
were harvested at day 8 after inoculation for the isolation of
leukocytes and were processed for flow cytometry [23].
Measurement of WNV-specific antibodies
The titers, defined as median fluorescent intensity, of
WNV-specific IgM and IgG antibodies were measured
in the serum of WNV NY99 and WNV Eg101 infected
mice using microsphere immunoassay (MIA) for WNV
envelope E protein [17, 24].
Plaque reduction neutralization test (PRNT)
The titers of anti-WNV neutralizing antibodies were mea-
sured in the serum of WNV NY99 and WNV Eg101 in-
fected mice using PRNT assay as described previously [17].
Serum collected from WNV NY99 and WNV Eg101 in-
fected mice were serially diluted from 1:40 to 1:5000, and
PRNT was conducted against WNV NY99 and WNV
Eg101 viruses, respectively. The highest dilution of serum
resulting in 80 % reduction in the number of plaques com-
pared to the growth of the virus control was determined as
described previously [17, 24, 25].
Measurement of cytokines and chemokines
The levels of cytokines and chemokines were measured
in the serum and brain homogenates by multiplex im-
munoassay using MILLIPLEX MAP Mouse Cytokine/
Chemokine kit (Millipore) [20, 23].
ELISA
The levels of IFN-α and IFN-β were measured in the serum
and brain homogenates by ELISA, using the VeriKine™
Mouse Interferon-α ELISA Kit and VeriKine™ Mouse
Interferon-β ELISA Kit (PBL Interferon Source) [20].
Immunohistochemistry
Sagittal sections of 10-μm thicknesses were cut from the
hemi-brain tissues frozen in OCT, and whole sagittal tis-
sue sections were stained with hematoxylin and eosin
(H&E) [23, 26].
Analysis of splenic leukocytes
Splenocytes were harvested from WNV NY99 and
WNV Eg101 infected mice on day 8 after inoculation.
Cells were counted and washed with 1X fluorescence-
activated cell sorter buffer. Cells were stained for CD45,
CD3, NK1.1, CD11b, and Ly6c by directly conjugated
antibodies (eBiosciences) for 30 min at 4 °C and then
fixed with 2 % PFA. Samples were analyzed by multi-
color flow cytometry using FACSAria, and data were an-
alyzed using FlowJo software [19, 23]. Briefly, after gat-
ing live cells by forward and side scatter (FSC and SSC)
parameters, CD45+ leukocytes were selected. CD45+ leu-
kocytes were further divided into CD3+, CD11b+, and
NK1.1+ cells. CD11b+ cells were further delineated into
subsets of CD11b+ Ly6C+ cells. CD3+ T cells were fur-
ther divided into the CD4+ and CD8+ subsets. The total
numbers of CD4+ T cells, CD8+ T cells, NK1.1+ cells,
and CD11b+ Ly6C+ cells from each spleen were deter-
mined by multiplying the percentage of these cells by
the total number of CD45+ leukocytes harvested as de-
scribed previously [23].
In separate experiments, 106 splenocytes were stimu-
lated with 2 μg/ml of an immunodominant WNV-
specific NS4B peptide (SSVWNATTAI) (21st Century
Biochemical) for 6 h at 37 °C in the presence of Golgi-
Plug (BD Biosciences). Splenocytes were stained with
anti-CD8 antibody for 30 min at 4 °C followed by fix-
ation and permeabilization (BD Biosciences) and stained
with anti-IFNγ and anti-TNF-α antibodies (eBiosciences)
for 30 min at 4 °C. Samples were analyzed by multi-
color flow cytometry using FACSAria, and the percent-
ages of CD8+ T cells that expressed IFNγ or TNF-α were
determined using FlowJo software [23].
Flow cytometric analysis of infiltrated immune cells in the
brain
Brains were harvested from WNV NY99 and WNV
Eg101 infected mice on day 8 after inoculation and
homogenized using a Miltenyi gentle MACS cell dis-
sociator (Miltenyi Biotec) and enzymatic neural dis-
sociation kit (Miltenyi Biotec). Infiltrated leukocytes
were isolated by discontinuous Percoll gradient cen-
trifugation. Cells were counted and washed once
with PBS. Cells were stained for CD45, CD3, NK1.1,
CD11b, and Ly6c by directly conjugated antibodies
(eBiosciences) for 30 min at 4 °C and then fixed with
2 % PFA. Samples were analyzed by multi-color flow
cytometry using FACSAria, and data were analyzed
using FlowJo software [19, 23]. Briefly, after gating
live cells by FSC and SSC parameters, CD45hi leuko-
cytes were selected. CD45hi leukocytes were further
divided into CD3+, CD11b+, and NK1.1+ cells as de-
scribed above [23].
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Statistical analysis
Log-rank (Mantel-Cox) Test and Gehan-Breslow-
Wilcoxon Test were used to analyze survival data.
Mann–Whitney test and unpaired Student t test using
GraphPad Prism 5.0 was used to calculate p values of
difference between viral titers and immune responses,
respectively. Differences of p < 0.05 were considered
significant.
Results
Morbidity and mortality in mice following WNV NY99 and
WNV Eg101 infection
Eight-week-old C57BL/6J mice were inoculated subcuta-
neously with 100 PFU of WNV Eg101 or WNV NY99 or
PBS (mock) and then monitored daily for clinical signs
and mortality. PBS inoculated mice remained healthy
throughout the observation period of 21 days. WNV
NY99 inoculated mice began to demonstrate clinical
signs at day 8 after inoculation and exhibited high
(65 %) mortality. In comparison, Eg101 inoculated mice
rarely displayed clinical signs of disease and no mortality
was observed in these mice (Fig. 1a, b). The difference in
mortality between WNV NY99 and WNV Eg101 in-
fected mice was statistically significant. All surviving ani-
mals were positive for anti-WNV IgG antibodies,
confirming virus infection (data not shown).
Viral load in the serum and brains of WNV NY99 and
WNV Eg101 infected mice
We first examined the WNV titers in the serum and
brains of WNV NY99 and WNV Eg101 infected mice by
plaque assay. High, but similar virus titers were detected
by plaque assay in the serum of both WNV NY99 and
WNV Eg101 infected mice at day 3 after inoculation
(Fig. 2a). At day 6 after inoculation, virus was cleared
from the periphery of all the WNV Eg101 infected mice;
however, it remained significantly high in WNV NY99
infected mice. The virus was cleared from the periphery
of all WNV NY99 infected mice by day 8 after inocula-
tion. WNV was not detected in the brains of both WNV
NY99 and WNV Eg101 infected mice at day 3 after in-
oculation, which is consistent with the previous studies
[20]. WNV was first detected in the brains at day 6 after
inoculation and peaked at day 8 after inoculation
(Fig. 2b). WNV titers in the brains of WNV NY99 in-
fected mice was slightly higher than WNV Eg101 in-
fected mice at day 6 after inoculation, but the difference
was not statistically significant. However, virus titers
were significantly higher in the brains of WNV NY99 in-
fected mice when compared to WNV Eg101 infected
mice at both days 8 and 10 after inoculation.
WNV-specific antibodies and type 1 interferon responses
in mice following WNV NY99 and WNV Eg101 infection
The titers of WNV-specific IgM and IgG antibodies in
the serum of WNV NY99 and WNV Eg101 infected
mice were measured using MIA. Infection with both
WNV NY99 and WNV Eg101 elicited robust WNV-
specific antibody responses. Anti-WNV IgM first ap-
peared at day 6 peaked at day 8 and then decreased at
day 10 after inoculation (Fig. 3a). Similarly, anti-WNV
IgG first appeared at day 6 and gradually increased up to
day 10 after inoculation (Fig. 3b). However, titers of both
IgM (days 6 and 8) and IgG (days 8 and 10) antibodies
were significantly higher in WNV NY99 infected mice
than WNV Eg101 infected mice. Similarly, titers of neu-
tralizing antibodies were also significantly higher in
WNV NY99 infected mice than WNV Eg101 infected
mice (Fig. 3c).
We measured the levels of IFN-α and IFN-β in the
serum of WNV NY99 and WNV Eg101 infected mice
using ELISA. High levels of IFN-α and IFN-β were de-
tected in the serum of both WNV NY99 and WNV






































Fig. 1 Survival analysis and clinical score of WNV NY99 and WNV Eg101 infected mice. a Eight-week-old C57BL/6J mice were inoculated subcutaneously
with 100 PFU of WNV NY99 or WNV Eg101. All mice were observed for 21 days. Data are combined of three independent studies (n= 24 mice per group).
b Animals were monitored for clinical scores twice a day. The designation for the clinical scores is as follows: 1, ruffled fur/hunched back; 2, paresis/difficulty
walking; 3, paralysis; 4, moribund/euthanized; and 5, dead. Error bars represent SEM. *p< 0.001, **p< 0.0001
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decreased gradually at days 6 and 8 after inoculation.
However, as demonstrated in Fig. 3d, e, we observed a
trend of slightly reduced levels of IFN-α and IFN-β in
the serum of WNV Eg101 infected mice at days 3 and 6
after inoculation. We also examined IFN-α and IFN-β
levels in the brains at days 8 and 10 after inoculation. In
the brain, as compared to WNV Eg101 which did not
elicit a strong interferon response, WNV NY99 infected
mice developed a robust interferon response at day 8
after inoculation. This response further decreased by day
10 after inoculation (Fig. 3f, g).
Peripheral cytokine and chemokine profiles in mice after
WNV NY99 and WNV Eg101 infection
It has been demonstrated that WNV-induced expression
of chemokines such as CCL2, CCL3, CCL4, CCL5, and
CXCL10 are associated with enhanced trafficking of leu-
kocytes into the brain [11, 27–29, 30–32]. WNV-induced
expression of pro-inflammatory cytokines such as IL-1β
and TNF modulate BBB permeability, facilitate leukocyte
trafficking into the brain, activate glial cells, and mediate
neuronal death after infection [13, 14]. Therefore, we
next assessed the protein levels of these cytokines and
chemokines in the serum of WNV NY99 and WNV
Eg101 infected mice using multiplex immunoassay. Very
low levels of these cytokines and chemokines were de-
tected in the serum of uninfected mice (day 0). WNV
NY99 infection resulted in a dramatic increase in protein
levels of multiple cytokines and chemokines at day 3
after inoculation, which further increased slightly at day
6 after inoculation (Fig. 4). We also observed a slight in-
crease in the levels of these cytokines and chemokines in
WNV Eg101 infected mice at day 3 after inoculation.
However, unlike WNV NY99 infected mice, there was
no increase in their levels at day 6 after inoculation.
Levels of interleukin (IL)-1β, −10, −13, and −15 were
significantly higher in WNV NY99 infected mice than
WNV Eg101 infected mice at day 6 after inoculation.
Similarly, TNF-α and GM-CSF levels in the serum of
WNV NY99 infected mice were significantly higher
when compared to WNV Eg101 infected mice at day 6
after inoculation. A similar pattern was also observed
for chemokine expression. CCL3 level was signifi-
cantly higher in WNV NY99 infected mice at day 6
after inoculation, whereas the level of CXCL10 was
significantly higher in WNV NY99 infected mice at
both days 3 and 6 after inoculation. The level of
CXCL1 was only increased significantly at day 3 after
inoculation when compared to WNV Eg101 mice.
However, the comparison of levels of serum cytokines
and chemokines, such as IL-6, CCL2, and CCL5 be-
tween both groups demonstrated no significant differ-
ences in their levels at any time point after inoculation
(Fig. 4).
Cytokine and chemokine profiles in the brains of WNV
NY99 and WNV Eg101 infected mice
We further examined the protein levels of multiple in-
flammatory cytokines and chemokines in the mice brain
homogenates following WNV NY99 and WNV Eg101
infection. Very low levels of these cytokines and chemo-
kines were detected in the brains of uninfected mice
(day 0). As expected, levels of multiple cytokines and
chemokines increased dramatically in WNV NY99 in-
fected mice brains at day 8 after inoculation, but this in-
crease was not observed in the brains of WNV Eg101
infected mice (Fig. 5). Levels of these cytokines and che-
mokines decreased slightly in the brains of WNV NY99
infected mice at day 10 after inoculation. In contrast,
there was a slight increase in the levels of these inflamma-
tory mediators in the brains of WNV Eg101 infected mice








































Fig. 2 Virus titers in the serum and brains of WNV NY99 and WNV Eg101 infected mice. The kinetics of virus replication and levels of WNV were
determined in the serum (a) and brains (b) of WNV NY99 or WNV Eg101 infected mice at indicated time points (days 3, 6, 8, and 10) by plaque
assay. The data are expressed as PFU/mL of serum and PFU/g of brain tissue. Error bars represent SEM (n = 6–10 mice per group). *p < 0.05.
Horizontal dotted line indicates the limit of detection
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IFNγ, GM-CSF, CCL5, CXCL2, and CXCL9 were signifi-
cantly higher in the brains of WNV NY99 infected mice
than WNV Eg101 infected mice at day 8 after inoculation.
Similarly, the levels of IL-13, IL-17, G-CSF, MCSF, CCL2,
and CCL11 were significantly higher in WNV NY99 in-
fected mice at both days 8 and 10 after inoculation when
compared to WNV Eg101 mice. However, the levels of IL-
6, TNF-α, CCL4, CXCL1, and CXCL5 were increased sig-
nificantly only at day 10 after inoculation when compared
to WNV Eg101 mice. Whereas, levels of IL-10, IL-12, LIF,
and CCL3 did not differ between WNV NY99 and WNV
Eg101 infected mice at any time point after inoculation
(Fig. 5).
Leukocyte accumulation in the spleens of WNV NY99 and
WNV Eg101 infected mice
Splenocytes were isolated from mock, WNV NY99 and
WNV Eg101 infected mice at day 8 after inoculation and
were analyzed by flow cytometry (Fig. 6). Cells were
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Fig. 3 WNV-specific IgM and IgG titers, neutralizing antibodies titers, and levels of IFN-α and IFN-β in mice following WNV NY99 and WNV Eg101
infection. Serum was collected from WNV NY99 and WNV Eg101 infected mice at indicated time points and WNV-specific IgM (a) and IgG (b) responses
were measured by MIA using WNV E antigen. Results are reported as median fluorescent intensity (MFI) per 100 microspheres. Data are expressed as
MFI ± SEM and is representative of two independent experiments (n = 8–16 mice per group). *p < 0.05, **p < 0.001. Horizontal dotted line indicates the
cutoff value. c Neutralizing antibodies titers in the serum of WNV NY99 and WNV Eg101 infected mice. Serum collected from WNV NY99 and WNV
Eg101 infected mice at indicated time points was serially diluted from 1:40 to 1:5000 and PRNT was conducted against WNV NY99 and WNV Eg101
viruses, respectively. Data are expressed as mean log10 titer ± SEM and is representative of two independent experiments (n = 8–16 mice per group).
IFN-α and IFN-β production was measured in the serum (d) and (e) collected from WNV NY99 and WNV Eg101 infected mice at indicated time points
using mouse IFN-α and mouse IFN-β ELISA kits and from brains (f) and (g) harvested from WNV NY99 and WNV Eg101 infected mice at days 6 and 8
after inoculation. The data are expressed as pg/mL of serum or pg/g of brain tissue. Error bars represent SEM (n = 6–8 mice per group).
*p < 0.05, **p < 0.001
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Ly6C markers to analyze both T cells and non-T cell
subpopulations. Interestingly, WNV Eg101 infected mice
spleens had significantly higher numbers of total leuko-
cytes (CD45+ cells), CD4+ T cells (CD45+ CD3+ CD4+),
CD8+ T cells (CD45+ CD3+ CD8+), NK cells (CD45+
CD3− NK1.1+), and monocytes/macrophages (CD45+
CD11b+ Ly6c+) than WNV NY99 infected mice spleen
(Fig. 6a). Additionally, the percentage of NK cells and
monocytes/macrophages in the spleens of WNV Eg101
infected mice were also higher than in WNV NY99 in-
fected mice (Fig. 6b). No difference was observed in the
percentage of T cells in the spleens of WNV Eg101 and
NY99 infected mice.
WNV-specific T cell responses in WNV NY99 and WNV
Eg101 infected mice
Splenocytes from mock, WNV NY99, and WNV Eg101
infected mice were harvested at day 8 after inoculation
and re-stimulated ex vivo with an immunodominant
WNV NS4B peptide, and CD8+T cells were analyzed for
the production of intracellular IFNγ and TNF-α by flow
cytometry. As depicted in Fig. 7a, b, total number and
percentage of CD8+ IFNγ+ cells (3.50 versus 1.65 %) and
CD8+ IFNγ+ TNF-α+ cells (2.82 versus 1.45 %) were
significantly higher in WNV Eg101 infected mice than
in WNV NY99 infected mice, respectively. We observed
no significant difference in the percentage of CD8+
TNF-α+ cells from WNV NY99 and WNV Eg101 in-
fected mice after incubation with WNV-specific peptide.
Leukocyte infiltration in the brain after WNV NY99 and
WNV Eg101 infection
We initially examined the mice brain tissues for histo-
pathological changes following WNV NY99 and WNV
Eg101 infection. As expected, H&E staining of brain sec-
tions from the WNV NY99 infected mice demonstrated
leukocyte infiltration along the meninges at day 8 after
inoculation (Fig. 8a). Interestingly, we observed higher
numbers of leukocytes in the meninges and parenchyma
of WNV Eg101 infected mice. To further verify these re-
sults, we isolated leukocytes from the brains of mock,
WNV NY99, and WNV Eg101 infected mice at day 8
after inoculation and analyzed by flow cytometry. Con-
sistent with our immunohistochemistry results, we ob-
served higher numbers of total leukocytes (CD45hi cells)
in the brains of WNV Eg101 infected mice (Fig. 8b),
which was statistically not significant. However, the total























































































































































Fig. 4 Cytokines and chemokines levels in the serum of WNV NY99 and WNV Eg101 infected mice. Serum was collected from WNV NY99 and
WNV Eg101 infected mice at indicated days after virus inoculation. Levels of chemokines and cytokines as noted in the figure were measured
using multiplex immunoassay and are expressed as the mean concentration (pg/mL) ± SEM, representing two independent experiments (n = 6–10
mice per group). *p < 0.05, **p < 0.001













































































































































































































































































































































































































































































Fig. 5 Cytokines and chemokines levels in the brains of WNV NY99 and WNV Eg101 infected mice. Brains were harvested from WNV NY99 and
WNV Eg101 infected mice at indicated time points and homogenized as described in the materials and methods section. Levels of cytokines
and chemokines as noted in the figure were measured using multiplex immunoassay and are expressed as the mean concentration (pg/g
of tissues) ± SEM, representing two independent experiments (n = 6 mice per group). *p < 0.05, **p < 0.001, ***p < 0.0001
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T cells (CD45hi CD3+ CD8+) trafficking into the brains
of WNV Eg101 infected mice were significantly higher
than in WNV NY99 infected mice. There was no differ-
ence between the numbers of NK cells (CD45hi CD3−
NK1.1+) and monocytes/macrophages (CD45hi CD11b+
Ly6c+) in the brains of WNV Eg101 and WNV NY99 in-
fected mice. As demonstrated in Fig. 8c, the percentage
of T cells in the brains of WNV Eg101 infected mice
was higher than in those of WNV NY99 infected mice
(43.5 versus 30.7 %). On the other hand, unlike the
spleen, the percentage of monocytes/macrophages was
lower in the brains of WNV Eg101 infected mice (33
versus 46.4 %). No difference between percentage of NK
cells in the brains of WNV Eg101 and WNV NY99 in-
fected mice was observed.
Discussion
In this study, NY99 and Eg101, two phylogenetically
closely related lineage 1 WNV strains (95.4 and 99.6 %
identical at the nucleotide and amino acid level, respect-
ively) of contrasting pathogenicity, were compared with
regard to induction of clinical disease and immune re-
sponses in the periphery and brain of mice. We observed
that both viral strains were neuroinvasive and induced a
robust anti-WNV immune response when inoculated
subcutaneously at similar doses. While the production of
type 1 interferon and WNV-specific antibodies were
higher in WNV NY99 infected mice, the innate and
adaptive cellular immune response was more predomin-
ant in WNV Eg101 infected mice. Furthermore, by dem-
onstrating that immune cells accumulation was higher
in the spleens and brains of mice infected with the non-
virulent WNV strain, we suggest that pathogenicity is
not directly correlated to the number of immune cells in
the spleen and brain. Moreover, our results demonstrat-
ing an inverse correlation between the number of
immune cells in the brain and the levels of pro-
inflammatory mediators indicate that WNV-infected/
activated resident brain cells not infiltrating immune
cells are the primary source of these inflammatory me-
diators and their increased levels correlate with high
brain viral load and severe WNV disease.
Enhanced WNV-specific antibodies, type 1 interferon and
inflammatory response in WNV NY99 infected mice
Despite the high degree of homology between the two
strains, WNV Eg101 is non-pathogenic in adult mice
after peripheral inoculation. WNV Eg101 infected mice
rarely displayed clinical signs and no mortality was ob-
served in these mice [17]. Similar to our study, it has
been demonstrated that peripheral inoculation of the
Eg101 strain into MBR/ICR albino Swiss mice rarely re-
sulted in fatal illness in mice older than 4 weeks. However,
direct intracranial inoculation of WNV Eg101 in same
age-matched mice was lethal [33], thereby suggesting the
role of peripheral immune response in limiting virus repli-
cation, neuroinvasion, and severe WNV disease in WNV


















































































Fig. 6 Leukocyte accumulation in the spleens of WNV NY99 and
WNV Eg101 infected mice. Spleens were harvested from mock, WNV
NY99, and WNV Eg101 infected mice after extensive perfusion at day 8
after inoculation. Splenocytes were isolated and analyzed by flow
cytometry. a Total number of leukocytes (CD45+), T cells (CD45+
CD3+), CD4+ T cells (CD45+ CD3+ CD4+), CD8+ T cells (CD45+ CD3+
CD8+), NK cells (CD45+ CD3− NK1.1+), and monocytes/macrophages
(CD45+ CD11b+ Ly6c+) per spleen. Data represents the mean ± SEM,
representing two independent experiments (n = 6 mice per group).
*p < 0.05. b Representative flow cytometry profiles demonstrating
percentages of NK cells, and monocytes/macrophages in the spleen at
day 8 after inoculation. Data represents two independent experiments
(n = 6 mice per group)
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was similar in mice after infection with both WNV NY99
and WNV Eg101 strains as demonstrated by high and
comparable viremia at day 3 after inoculation in both the
groups. However, viremia in WNV Eg101 infected mice
was short-lived than WNV NY99 infected mice, suggest-
ing the induction of an early and effective immune re-
sponse in these mice. It has been demonstrated that type I
interferon and WNV-specific immunoglobulins are rapidly
produced following WNV infection and are essential for
suppressing viremia and virus dissemination [8, 9]. In this
study, we also observed a rapid and robust production of
type I interferon and WNV-specific antibodies in both
groups. Surprisingly, we observed reduced levels of IFN-α
and IFN-β, WNV-specific IgM and IgG antibodies and
neutralizing antibodies, in the serum of WNV Eg101 in-
fected mice than WNV NY99 infected mice.
Similar to interferon and WNV-specific immunoglob-
ulins, WNV-induced pro-inflammatory mediators are
also known to protect mice from lethal WNV disease
[11, 14, 31]. TNF-α and IL-1β promotes immune cell
trafficking into the brain [14, 31]. CXCL10 promotes
trafficking of WNV-specific CD8+ T cells via binding to
its cognate receptor CXCR3 [11]. Enhanced expression
of CCL3, CCL4, and CCL5 by WNV infection leads to
CCR5-dependent trafficking of CD4+ and CD8+ T cells,
NK cells, and macrophages into the brain [32]. CCL2 is
important in the trafficking of inflammatory monocyte
into the brain after WNV infection [33]. Interestingly in
this study, we observed an enhanced production of key
pro-inflammatory cytokines and chemokines in the
serum of WNV NY99 infected mice than WNV Eg101
infected mice despite increased mortality observed in
WNV NY99 infected mice. One possible explanation
for these differences is increased viral antigen load in
WNV NY99 infected mice, leading to enhanced type 1
interferon, antibodies, and inflammatory mediators in
these mice.
Increased WNV-specific innate and adaptive immune cell
response in WNV Eg101 infected mice
WNV dissemination is also countered by the effector
functions of innate and adaptive immune cells. Several
studies have demonstrated that immune cells such as
monocyte/macrophages and T cells play an indispens-
able role in the control of WNV infection [10, 12, 34].
The role of NK cells in regulating tissue tropism to
WNV infection or in controlling WNV replication in
vivo has not been clearly defined [35, 36]. However, vari-
ous in vitro and ex vivo studies have suggested their role
in the control of WNV infection by their recognition
and elimination of infected cells [37, 38].
Unlike the interferon and inflammatory response, we
observed significantly higher numbers of total leuko-
cytes, T cells, NK cells, and monocytes/macrophages in
the spleens of WNV Eg101 infected mice. Moreover,
total number and percentage of IFN-γ and TNF-α pro-
ducing WNV-specific CD8 T cells were also significantly
higher in WNV Eg101 infected mice. This is surprising
as interferon and various inflammatory mediators have
been demonstrated to enhance immune cell responses in
WNV infection [39–41]. Another interesting finding is
the increased percentage of NK cells and monocytes/
macrophages observed in the spleens of WNV Eg101 in-














Fig. 7 T cell responses in the spleens following WNV NY99 and WNV Eg101 infection. Spleens were harvested after extensive perfusion of mock,
WNV NY99, and WNV Eg101 infected mice at day 8 after inoculation. Splenocytes were isolated and stimulated ex vivo for 6 h with an immunodominant
NS4B peptide as described in the materials and methods. Cells were co-stained for CD8 and intracellular IFN-γ and TNF-α and analyzed by flow cytometry.
a Total number of CD8+ TNF-α+ cells, CD8+ IFNγ+ cells, and CD8+ TNF-α+ IFNγ+ cells. Data represents the mean ± SEM, representing two
independent experiments (n = 6 mice per group) *p < 0.05, ***p < 0.0001. b Representative flow cytometry profiles demonstrating percentages
of CD8+ TNF-α+ cells, CD8+ IFNγ+ cells, and CD8+ TNF-α+ IFNγ+ cells. Data represents two independent experiments (n = 6 mice per group)
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immune cells in limiting virus replication in these
mice. Collectively, these data demonstrate that induc-
tion of virus-specific effector immune cell response
limits virus replication and severe WNV disease in
Eg101 infected mice.
It could be argued that differences in virulence ob-
served after infection with WNV NY99 and WNV
Eg101 strains in this study are virus dose-dependent. For
example, a lower dose (10 PFU) of WNV NY99 could
give similar results to those seen with 100 PFU of WNV
Eg101, or a higher dose of WNV Eg101 (1000 PFU)
could give similar results to those seen with 100 PFU of
WNV NY99. However, our previously published data
demonstrate that a lower dose (10 PFU) of WNV NY99
results in 37 % mortality when compared to 0 % mortal-
ity as observed with 100 PFU of WNV Eg101 [19, 20].
This data clearly demonstrates that a lower dose of
WNV NY99 (10 PFU) does not give similar results to
those observed with 100 PFU of WNV Eg101. Moreover,
our published data demonstrate no significant difference
in terms of survival, clinical score, viremia, WNV-
specific IgG and IgM antibodies, and neutralizing anti-
bodies in mice infected with different doses (100 or 1000
PFU) of WNV Eg101 [17].
WNV entry and replication into the CNS represents
an important event in the clinical outcome of WNV dis-
ease. Following WNV infection, immune cells, especially
T cells and macrophages, travel into the brain and
Fig. 8 Infiltration of leukocytes in the brains of WNV NY99 and WNV Eg101 infected mice. a PFA-fixed brain sections from WNV NY99 and WNV
Eg101 infected mice at day 8 after inoculation were stained with hematoxylin and eosin (H & E). Black arrows identify leukocytes infiltrating into
the meninges. The photomicrographs demonstrate representative images obtained from two independent experiments (n = 4 mice per group).
b Brains were harvested from mock, WNV NY99, and WNV Eg101 infected mice at day 8 after inoculation, and leukocytes were isolated by Percoll
gradient centrifugation. Total number of leukocytes (CD45hi), T cells (CD45hi CD3+), CD4+ T cells (CD45hi CD3+ CD4+), CD8+ T cells (CD45hi CD3+
CD8+), NK cells (CD45hi CD3− NK1.1+), and monocytes/macrophages (CD45hi CD11b+ Ly6c+) per brain were analyzed using flow cytometry. Data
represents the mean ± SEM, representing two independent experiments (n = 6 mice per group). *p < 0.05. c Representative flow cytometry profiles
demonstrating percentages of T cells and monocytes/macrophages in the brains at day 8 after inoculation. Data represents two independent experi-
ments (n = 6 mice per group)
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participate in viral clearance [10, 12, 34]. Moreover, the
production of IFN-α and –β is essential in suppressing
virus replication in the brain [8]. In this study, we ob-
served significantly higher virus titers in the brains of
WNV NY99 infected mice when compared to WNV
Eg101 infected mice at both days 8 and 10 after inocula-
tion. Similar to the periphery, the levels of IFN-α and -β
were significantly lower in the brains of WNV Eg101 in-
fected mice. Interestingly, similar to the spleen, the total
number of immune cells migrating into the brains of
WNV Eg101 infected mice was higher than in WNV
NY99 infected mice. However, unlike the spleen, we only
observed a significantly higher number of T cells in the
brains of WNV Eg101 infected mice. No difference was
observed between the number of NK cells and mono-
cytes/macrophages in the brains of WNV Eg101 and
WNV NY99 infected mice. Similarly, we also observed a
high percentage of T cells in the brains of WNV Eg101
infected mice. On the other hand, we observed a low
percentage of monocytes/macrophages in the brains of
WNV Eg101 infected mice. Collectively, these data are
consistent with previous observations that virus-specific
T cells are the predominant cell types in clearing WNV
from the brain.
Absence of functional CD8+ or CD4+ T cells resulted
in failure to clear WNV from infected neurons in the
CNS [10,12]. It has been demonstrated that increased
CD8+ T cells contribute to the immunopathology with
high doses of WNV challenge [42]. It is also known that
migration of inflammatory monocytes plays a pathogenic
role during WNVE [33, 43, 44]. Similarly, immune cell-
mediated pathology in the brain has been demonstrated
in several neurotropic virus infections such as tick-borne
encephalitis virus, Murray Valley encephalitis virus, and
Theiler's murine encephalomyelitis virus [45–48]. How-
ever, in this study, we did not observe any immunopa-
thology associated with increased immune cell migration
into the brains of WNV Eg101 infected mice. This may
be due to significantly low levels of inflammatory media-
tors in the brains of WNV Eg101 infected mice.
Negative correlation between migrating immune cells
and associated inflammation
One of the most intriguing findings of our study was the
difference in the inflammatory responses observed in the
brain. The migration of leukocytes into WNV-infected
brain is associated with increased expression of several
cytokines and chemokines in the brain. Also, increased
expression of cytokines and chemokines in the WNV-
infected brain is usually associated with enhanced traf-
ficking of leukocytes into the brain [11, 14, 32]. In con-
trast, we demonstrate that increased accumulation of
leukocytes in the brains of WNV Eg101 (non-virulent
strain) infected mice was associated with reduced
production of pro-inflammatory cytokines and chemo-
kines. This phenomenon of significantly increased mi-
gration of leukocytes in to the brain of WNV Eg101
infected mice despite reduced production of chemokines
and cytokines could be due to the higher numbers of
WNV-specific primed cells in the periphery of these
mice. Lower numbers of infiltrating cells in the brains of
WNV NY99 infected mice could be due to different che-
mokine receptor expression on the leukocytes leading to
differential responsiveness to the chemokines emanating
from the brain. Differential virus cytopathic effects of
WNV NY99 and WNV Eg101 viruses could also result
in difference in leukocytes numbers observed in the
brain and spleen. Moreover, we observed a dramatic in-
crease in various chemokine and cytokine levels in the
brains of WNV NY99 (virulent strain) mice, which cor-
relates with high brain viral load detected in these mice.
These data indicate that infiltrating immune cells may
play a limited role in the production of these inflamma-
tory mediators and WNV-infected/activated resident
brain cells are the primary source(s) of these inflamma-
tory mediators in the brain. However, our data do not
rule out the possibility that monocytes/macrophages/
microglial may be less activated in Eg101 infected mice
brains and may produce less pro-inflammatory cyto-
kines, or the infiltrating immune cell population is sup-
pressing/regulating brain cytokine production.
Resident brain cells such as neurons and astrocytes
have been associated with producing inflammatory me-
diators in several neuroinflammatory scenarios including
WNV infection. It has been previously demonstrated by
us and others that WNV-infected neurons directly con-
tribute to inflammation by secreting various chemokines
and cytokines [11, 13]. Similarly, we and others have
previously demonstrated that WNV-infected and acti-
vated astrocytes can produce high levels of cytokines
and chemokines [49, 50]. Recent studies of WNV infec-
tion in brain slices cultures demonstrate the ability of
the brain cells to produce pro-inflammatory cytokine re-
sponse and to activate astrocytes and microglial cells in
the absence of infiltrating inflammatory cells and sys-
temic immune responses [51, 52].
Neuronal death is the hallmark of WNVE. Like sev-
eral encephalitic viruses, WNV induces neuronal death
both in a direct or indirect manner, and in the latter
case, through inflammation [13, 53, 54]. Therefore, in-
creased neuronal death and subsequent pathology in
WNV NY99 infected mice could be due to (i) virus-
mediated neuronal apoptosis and (ii) bystander neur-
onal damage due to pro-inflammatory molecules
released by resident brain cells, such as neurons and
activated glial cells. Taken together, these data demon-
strate that induction of effective and balanced immune
response in the periphery and brain of WNV Eg101
Kumar et al. Journal of Neuroinflammation  (2015) 12:178 Page 12 of 14
infected mice limits virus replication and severe WNV
disease in these mice.
Conclusions
In conclusion, we demonstrate that effector functions of
specific innate and adaptive immune cell subsets protect
mice against WNV Eg101 disease. Increased migration
of immune cells in the brain is not associated with en-
hanced production of pro-inflammatory mediators and
associated immunopathology in mice. In contrast, in-
creased production of pro-inflammatory mediators was
associated with high-virus titers and increased mortality
in WNV NY99 infected mice. To our knowledge, this is
the first comprehensive study to examine the immuno-
logical changes in mice after infection with a naturally
non-virulent strain of WNV and will assist to under-
stand the underlying immunopathological mechanisms
leading to severe WNV disease.
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